logo.jpg
Genmab and Synaffix Enter into License Agreement for ADC Technology
04 janv. 2022 09h00 HE | Genmab A/S
Media Release Synaffix to provide access to proprietary antibody-drug conjugate (ADC) technologiesGenmab secures rights for conducting research on ADCs against multiple drug targets with options for...